nach oben

Erschienen in:

26.10.2016 | Preclinical study

Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast

verfasst von: Michael J. Campbell, Frederick Baehner, Tess O’Meara, Ekene Ojukwu, Booyeon Han, Rita Mukhtar, Vickram Tandon, Max Endicott, Zelos Zhu, Jasmine Wong, Gregor Krings, Alfred Au, Joe W. Gray, Laura Esserman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The recent increase in the incidence of ductal carcinoma in situ (DCIS) has sparked debate over the classification and treatment of this disease. Although DCIS is considered a precursor lesion to invasive breast cancer, some DCIS may have more or less risk than is realized. In this study, we characterized the immune microenvironment in DCIS to determine if immune infiltrates are predictive of recurrence.

Methods

Fifty-two cases of high-grade DCIS (HG-DCIS), enriched for large lesions and a history of recurrence, were age matched with 65 cases of non-high-grade DCIS (nHG-DCIS). Immune infiltrates were characterized by single- or dual-color staining of FFPE sections for the following antigens: CD4, CD8, CD20, FoxP3, CD68, CD115, Mac387, MRC1, HLA-DR, and PCNA. Nuance multispectral imaging software was used for image acquisition. Protocols for automated image analysis were developed using CellProfiler. Immune cell populations associated with risk of recurrence were identified using classification and regression tree analysis.

Results

HG-DCIS had significantly higher percentages of FoxP3⁺ cells, CD68⁺ and CD68⁺PCNA⁺ macrophages, HLA-DR⁺ cells, CD4⁺ T cells, CD20⁺ B cells, and total tumor infiltrating lymphocytes compared to nHG-DCIS. A classification tree, generated from 16 immune cell populations and 8 clinical parameters, identified three immune cell populations associated with risk of recurrence: CD8⁺HLADR⁺ T cells, CD8⁺HLADR⁻ T cells, and CD115⁺ cells.

Conclusion

These findings suggest that the tumor immune microenvironment is an important factor in identifying DCIS cases with the highest risk for recurrence and that manipulating the immune microenvironment may be an efficacious strategy to alter or prevent disease progression.

Siziopikou KP (2013) Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med 137(4):462–466. doi:10.5858/arpa.2012-0078-RA CrossRefPubMed

Bianchi S, Vezzosi V (2008) Microinvasive carcinoma of the breast. Pathol Oncol Res 14(2):105–111. doi:10.1007/s12253-008-9054-8 CrossRefPubMed

Rosner D, Lane WW, Penetrante R (1991) Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer 67(6):1498–1503CrossRefPubMed

Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, Goodman RL (1992) Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 23(5):961–968CrossRefPubMed

Esserman L, Yau C (2015) Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 1(7):881–883. doi:10.1001/jamaoncol.2015.2607 CrossRefPubMed

Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1(7):888–896. doi:10.1001/jamaoncol.2015.2510 CrossRefPubMed

Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387. doi:10.1200/JCO.2006.06.1366 CrossRefPubMed

Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271PubMed

Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16(2):441–452PubMed

10.

Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418CrossRefPubMed

11.

Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S (2008) Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 26(8):1247–1252. doi:10.1200/JCO.2007.12.7969 CrossRefPubMed

12.

Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102CrossRefPubMed

13.

Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM (2006) Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 24(28):4603–4610. doi:10.1200/JCO.2005.04.5518 CrossRefPubMedPubMedCentral

14.

Wai ES, Lesperance ML, Alexander CS, Truong PT, Moccia P, Culp M, Lindquist J, Olivotto IA (2011) Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. Ann Surg Oncol 18(1):119–124. doi:10.1245/s10434-010-1214-x CrossRefPubMed

15.

Kurniawan ED, Rose A, Mou A, Buchanan M, Collins JP, Wong MH, Miller JA, Mann GB (2010) Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 145(11):1098–1104. doi:10.1001/archsurg.2010.243 CrossRefPubMed

16.

Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186(4):337–343CrossRefPubMed

17.

Silverstein MJ, Lagios MD (2015) Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J 21(2):127–132. doi:10.1111/tbj.12368 CrossRefPubMed

18.

Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS (2015) Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 4(9):e985930. doi:10.4161/2162402X.2014.985930 CrossRefPubMedPubMedCentral

19.

Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ (2011) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128(3):703–711. doi:10.1007/s10549-010-1154-y CrossRefPubMed

20.

de la Cruz-Merino L, Barco-Sanchez A, Henao Carrasco F, Nogales Fernandez E, Vallejo Benitez A, Brugal Molina J, Martinez Peinado A, Grueso Lopez A, Ruiz Borrego M, Manuel Codes, de Villena M, Sanchez-Margalet V, Nieto-Garcia A, Alba Conejo E, Casares Lagar N, Ibanez Martinez J (2013) New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013:785317. doi:10.1155/2013/785317 PubMedPubMedCentral

21.

Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Investig 123(7):2873–2892. doi:10.1172/JCI67428 CrossRefPubMedPubMedCentral

22.

Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA (2014) The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat 148(3):467–476. doi:10.1007/s10549-014-3185-2 CrossRefPubMed

23.

Jiang D, Gao Z, Cai Z, Wang M, He J (2015) Clinicopathological and prognostic significance of FOXP3⁺ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer 15(1):727. doi:10.1186/s12885-015-1742-7 CrossRefPubMedPubMedCentral

24.

Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, Gong G (2015) Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol 69(5):422–430. doi:10.1136/jclinpath-2015-203089 CrossRefPubMed

25.

Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J (2015) Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 68(7):506–510. doi:10.1136/jclinpath-2015-202944 CrossRefPubMed

26.

Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, Ishida T (2015) Prognostic significance of tumor-infiltrating CD8⁺ and FOXP3⁺ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 17(1):124. doi:10.1186/s13058-015-0632-x CrossRefPubMedPubMedCentral

27.

Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11(1):91–100. doi:10.1586/erm.10.97 CrossRefPubMed

28.

Obeid E, Nanda R, Fu YX, Olopade OI (2013) The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 43(1):5–12. doi:10.3892/ijo.2013.1938 PubMedPubMedCentral

29.

Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J (2010) Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev 29(4):569–579. doi:10.1007/s10555-010-9247-y CrossRefPubMed

30.

Lee AH, Happerfield LC, Bobrow LG, Millis RR (1997) Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol 181(2):200–206. doi:10.1002/(SICI)1096-9896(199702)181:2<200:AID-PATH726>3.0.CO;2-K CrossRefPubMed

31.

Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA (1990) Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma–a detailed morphological analysis. J Pathol 161(1):7–14. doi:10.1002/path.1711610104 CrossRefPubMed

32.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES (2013) FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 139(2):381–390. doi:10.1007/s10549-013-2556-4 CrossRefPubMed

33.

Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB (2010) Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 123(2):397–404. doi:10.1007/s10549-009-0654-0 CrossRefPubMed

34.

Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM (2006) Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7(10):R100. doi:10.1186/gb-2006-7-10-r100 CrossRefPubMedPubMedCentral

35.

Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, Ljosa V, Rueden C, Eliceiri KW, Carpenter AE (2011) Improved structure, function and compatibility for cell profiler: modular high-throughput image analysis software. Bioinformatics 27(8):1179–1180. doi:10.1093/bioinformatics/btr095 CrossRefPubMedPubMedCentral

36.

Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249–258. doi:10.1038/modpathol.2015.158 CrossRefPubMed

37.

Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710. doi:10.1093/jnci/djt067 CrossRefPubMedPubMedCentral

38.

Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S (2015) Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Mod Pathol 28(9):1167–1173. doi:10.1038/modpathol.2015.79 CrossRefPubMed

Titel: Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast
verfasst von: Michael J. Campbell
Frederick Baehner
Tess O’Meara
Ekene Ojukwu
Booyeon Han
Rita Mukhtar
Vickram Tandon
Max Endicott
Zelos Zhu
Jasmine Wong
Gregor Krings
Alfred Au
Joe W. Gray
Laura Esserman
Publikationsdatum: 26.10.2016
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-4036-0

Springer Medizin

Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast